REIMAGINE 2 was a 68-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus semaglutide 2.4 mg, semaglutide 1 mg, cagrilintide 2.4 mg, and placebo in 2,713 adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor
A high-quality, properly formulated oral BPC-157 capsule is already designed with enteric protection to withstand stomach acid
Potent aromatase inhibitors and molecular mechanism of inhibitory action
The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis later reported 28.7% mean weight loss at 68 weeks with retatrutide 12 mg/week, and identified a dose-related dysesthesia (nerve-tingling) signal in 8.8% of 9 mg and 20.9% of 12 mg patients (Bays et al., 2025)
B12 vitamin shots begin working right away and your body will begin to manufacture new red blood cells as early as 48 hours
BPC-157 (5mg) Description A single-component research material supplied for controlled research environments